Kenneth M. Ferguson - Jun 14, 2022 Form 4/A - Amendment Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)

Role
Director
Signature
/s/ Kenneth M. Ferguson
Stock symbol
CYCC
Transactions as of
Jun 14, 2022
Transactions value $
$0
Form type
4/A - Amendment
Date filed
6/17/2022, 04:06 PM
Date Of Original Report
Jun 16, 2022
Next filing
Jul 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYCC Common Stock Award $0 +23.7K $0.00 23.7K Jun 14, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYCC Stock Option (right to buy) Award $0 +47.5K $0.00 47.5K Jun 14, 2022 Common Stock 47.5K $1.11 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person received an award of 23,733 restricted stock units on June 14, 2022, which shall vest in three equal installments on June 14, 2023, June 14, 2024, and June 14, 2025.
F2 This Form 4 is being amended to correct a typographical error in the number of restricted stock units granted to the Reporting Person on June 14, 2022. 23,733 shares of restricted stock units were granted to the Reporting Person.
F3 The option will vest and become exercisable in equal monthly installments for thirty-six months beginning on the date of the grant, which is June 14, 2022, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date.
F4 These options were granted to Mr. Ferguson for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.